Infectious disease biotech undergoes makeover after lung disease trial underwhelms
AN2 Therapeutics said it will shut down a late-phase study of its lead candidate in bacterial lung disease and then go through a company overhaul …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
